TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

Date: 12-11-2026

To,
BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street,
Mumbai — 400 001

Dear Sir/Madam,

Scrip Code: 539428

Subject: Submission of Un-Audited Financial Results (Standalone & Consolidated) for the Quarter ended on 30th September, 2026.

Please find the enclosed herewith Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended on 30th September, 2026 along with Limited Review Report thereon approved by the Board of Directors of the Company at its Meeting held on **Thursday, 12th November, 2026** at **Shop No 1 Building Name: Shivprasad Harihar Singh Compound, Block Sector: Jogeshwari East, Road: Caves Road. Pratap Nagar -Mumbai, Maharashtra, 400060** at 3:00 p.m., in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you.

For Tejnaksh Healthcare Limited

Rawandale

Tejnaksh Healthcare Limited MUMBAI

Dr. Ashish V. Rawandale
Managing Director
DIN: - 02005733

Independent Auditor's Review Report on Unaudited Standalone Financial Results of Tejnaksh Healthcare Limited for the Quarter and half year ended September 30, 2026 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to,
The Board of Directors
Tejnaksh Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Tejnaksh Healthcare Limited** ('hereinafter referred to as 'the Company') for the quarter and half year ended September 30, 2026 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Regulations").

2. This Statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') as amended, read with relevant rules issued thereunder ('Ind AS 34') and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the quarter ended September 30, 2026, as reported in the Statement, represent the balancing figures between the unaudited figures for the half year ended September 30, 2026, and the published unaudited figures for the quarter ended June 30, 2026. The figures up to the end of the second quarter of financial year had only been reviewed and not subjected to audit

5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.: 105834W



Vikas Asawa
(Partner)
Membership No.: 172133
UDIN: 26172133MJRAPR5229

Place: Mumbai
Date: November 12, 2026

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
(CIN: L85100MH2008PLC179034)
Standalone Balance Sheet As At September 30, 2026
All amounts are in Indian Rupees lakhs

Particulars	As at September 30, 2026	As at March 31, 2026
ASSETS		
Non-current assets		
Property, plant and equipment	1,703.48	1,738.14
Goodwill	147.61	168.70
Other intangible assets	0.93	0.95
Intangible assets under development	187.25	169.25
ROU assets	18.20	24.27
Financial assets		
-Investment	106.01	106.01
-Other financial assets	378.37	226.54
Income tax assets (net)	35.56	43.04
Other non current assets	0.63	0.74
Total non-current assets	**2,578.04**	**2,477.64**
Current assets		
Inventories	40.33	39.02
Financial assets		
-Trade receivables	218.62	201.73
-Cash and cash equivalents	136.46	178.55
-Other bank balances	17.80	7.74
-Other financial assets	3.72	3.53
Other current assets	8.57	13.47
Total current assets	**425.50**	**444.04**
Total assets	**3,003.54**	**2,921.68**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,015.68	1,015.68
Other equity	1,729.48	1,663.87
Total equity	**2,745.16**	**2,679.55**
Liabilities		
Non-current liabilities		
Financial liabilities		
-Borrowings	-	-
-Lease Liability	7.03	13.66
-Other Financial Liability	32.46	30.07
Provisions	8.60	8.78
Deferred Tax liabilities (Net)	150.20	146.40
Other non current liabilities	1.38	3.63
Total non-current liabilities	**199.67**	**202.54**
Current liabilities		
Financial liabilities		
-Borrowings	-	-
-Lease liability	12.27	10.96
-Trade payables		
Total outstanding dues of micro and small enterprises ; and	0.27	-
Total outstanding dues of creditors other than micro enterprises and small enterprises	30.95	11.07
Other Financial Liabilities	4.05	5.03
Other current liabilities	6.01	7.87
Provisions	5.16	4.66
Total current liabilities	**58.71**	**39.59**
Total liabilities	**258.38**	**242.13**
Total equity and liabilities	**3,003.54**	**2,921.68**

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
(CIN: L85100MH2008PLC179034)
Standalone Cash Flow Statement for half year ended on Sepetember 30, 2026
All amounts are in Indian Rupees lakhs

Particulars	Period ended September 30, 2026	Year ended March 31, 2026
Cash flow from/(used in) operating activities		
Profit /(loss) before tax	**92.30**	**178.56**
Adjustment for:		
Depreciation and amortisation expense	65.16	131.32
Interest Income	(9.75)	(12.18)
Finance costs	2.55	13.17
Employee Benefit expense (Gratuity)	0.80	(3.04)
Operating cash flows before working capital changes	**151.06**	**307.83**
Changes in working capital		
Adjustments for (increase) / decrease in operating assets:		
Trade receivables	(16.89)	(26.46)
Inventories	(1.31)	(2.07)
Other Financial assets	(152.02)	(92.23)
Other assets	5.01	104.46
Adjustments for increase / (decrease) in operating liabilities:		
Trade payables	20.15	(4.37)
Other Financial Liabilities	1.42	(15.85)
Other liabilities	(4.11)	(10.18)
Cash generated from /(used in) operations	**3.31**	**261.13**
Income taxes (paid)/refund (net)	(15.90)	(81.91)
Net Cash from / (used in) operating activities	**(12.59)**	**179.22**
Cash flow from investing activities		
Purchase of property, plant and equipment (including capital work-in-progress, intangibles assets and RoU)	(21.32)	(51.36)
Proceeds from sale of property, plant and equipment (including capital work-in-progress and intangibles)	-	2.25
Movement in other bank balance	(10.06)	(4.16)
Interest received	9.75	12.18
Net Cash from / (used in) investing activities	**(21.63)**	**(41.09)**
Cash flow from financing activities		
Principal element of lease payment	(5.32)	(8.97)
Repayment of long-term borrowings	-	(105.27)
Interest paid	(2.55)	(6.22)
Cash generated from /(used in) financing activities	**(7.87)**	**(120.46)**
Net increase/(decrease) in cash and cash equivalents	(42.09)	17.67
Cash and cash equivalent at beginning of the year	178.55	160.88
Cash and cash equivalent at end of the year	**136.46**	**178.55**
Reconciliation of cash and cash equivalents as per the cash flow statement:		
Cash and cash equivalents as per above comprise of the following:		
Balance with banks in current accounts	46.26	109.49
Cash on hand	90.20	69.06
	136.46	**178.55**

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
(CIN: L85100MH2008PLC179034)
Statement of Standalone Financial Results for quarter and half year ended on September 30, 2026
All amounts are in Indian Rupees lakhs

Particulars	Quarter Ended			Half year Ended		Year Ended
	Sep-26 Unaudited	Jun-26 Unaudited	Sep-25 Unaudited	Sep-26 Unaudited	Sep-25 Unaudited	Mar-26 Audited
REVENUE						
Revenue from operations (net)	182.89	184.29	193.53	367.18	371.58	717.72
Other income	9.58	9.03	8.22	18.61	16.64	37.42
Total Income	**192.47**	**193.32**	**201.74**	**385.79**	**388.22**	**755.14**
EXPENSES						
Cost of Materials Consumed	1.03	0.20	0.33	1.23	0.40	4.79
Purchases of stock-in-trade	13.48	13.99	10.53	27.47	22.42	43.69
Changes In Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	0.77	(2.08)	2.44	(1.31)	(2.96)	(3.07)
Employee benefits expense	12.94	14.69	25.79	27.63	44.26	77.69
Finance costs	1.36	1.19	4.27	2.55	8.60	13.17
Depreciation and amortization expense	32.59	32.58	32.92	65.16	65.73	131.32
Other expenses	83.10	87.66	83.15	170.76	162.39	308.99
Total Expenses	**145.27**	**148.23**	**159.43**	**293.49**	**300.84**	**576.58**
Profit before Exceptional Items & Tax	**47.21**	**45.10**	**42.31**	**92.30**	**87.38**	**178.56**
Exceptional Items	-			-	-	-
Profit/(Loss) Before Tax	**47.21**	**45.10**	**42.31**	**92.30**	**87.38**	**178.56**
Tax expense:						
Current tax	11.56	11.82	8.57	23.38	16.07	43.19
Deferred tax	(0.49)	4.17	2.70	3.68	6.54	(2.61)
Profit /(Loss) for the period/year	**36.13**	**29.11**	**31.04**	**65.24**	**64.77**	**137.98**
Other Comprehensive Income/(Loss)						
Items that will not be reclassified to profit or loss :						
Remeasurement of defined employee benefit plans	0.62	(0.13)	0.34	0.49	0.68	0.98
Income tax effect on above	(0.15)	0.03	(0.08)	(0.12)	(0.17)	(0.25)
Total Other Comprehensive income for the year, net of tax	**0.47**	**(0.10)**	**0.26**	**0.37**	**0.51**	**0.73**
Total Comprehensive Income (Net of Tax) for the Period/Year	**36.60**	**29.01**	**31.30**	**65.61**	**65.28**	**138.71**
Paid Up Equity Share Capital (face value 5/- each)	1,015.68	1,015.68	1,015.68	1,015.68	1,015.68	1,015.68
Reserves and surplus during the period						1,663.87
Earnings per share (EPS)						
Basic and Diluted Earing Per Share	0.18	0.14	0.15	0.32	0.32	0.68
			Not Annualized			Yearly

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

Notes to the Standalone Financial Results for the period ended September 30, 2026

1. The above statement of standalone unaudited interim financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 12, 2026. The Statutory Auditors have carried out limited review of the statement of standalone unaudited interim financial results for the quarter and half year ended September 30, 2026 and have issued an unmodified conclusion on the same.
2. The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") 34 – Interim Financial Reporting as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.
3. The figures for the quarter ended September 30, 2026, represent the derived figures, being the difference between the unaudited figures for the six months ended September 30, 2026, and the published unaudited figures for the quarter ended June 30, 2026, which were subjected to limited review by the Statutory Auditors.
4. The Company's business activity primarily falls within a single reportable business segment namely " Medical and Healthcare Services" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind As 108- "Segment Reporting".
5. Previous year/ period figures have been regrouped to make them comparable with the current year/ period figures, wherever applicable, which are not material.

For and on behalf of Board of Directors of

Tejnaksh Healthcare Limited

Tejnaksh Healthcare Limited MUMBAI

Dr. A. V. Rawandale
Managing Director
DIN: 02005733

Date: November 12, 2026
Place: Mumbai

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of Tejnaksh Healthcare Limited for the quarter and half year ended September 30, 2026 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to
The Board of Directors
Tejnaksh Healthcare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Tejnaksh Healthcare Limited** ('hereinafter referred to as 'the Parent') and its subsidiaries (the parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2026 (the 'Statement'), attached herewith, being submitted by the Parent pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Regulations").

2. This Statement which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') as amended, read with relevant rules issued thereunder ('Ind AS 34') and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The statement includes the results of the following entities:
   a. **Holding Company**: Tejnaksh Healthcare Limited
   b. **Subsidiary**: Tej Vedaant Healthcare Private Limited

5. Attention is drawn to the fact that the figures for the quarter ended September 30, 2026, as reported in the Statement, are the balancing figures between the unaudited figures for the half year ended September 30, 2026, and the published unaudited figures for the quarter ended June 30, 2026, which were subjected to limited review by the Statutory Auditors. The figures up to the end of the second quarter of financial year had only been reviewed and not subjected to audit.

MAHESHWARI & CO. FRN:105834W MUMBAI Chartered Accountants

6. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.: 105834W

Vikas Asawa
(Partner)
Membership No.: 172133
UDIN: 26172133VTZIEH4216

MAHESHWARI & CO
FRN:105834W
MUMBAI
Chartered Accountants

Place: Mumbai
Date: November 12, 2026

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
(CIN:L85100MH2008PLC179034)
Consolidated Balance Sheet as at September 30, 2026
All amounts are in Indian Rupees lakhs

Particulars	As at September 30, 2026	As at March 31, 2026
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	1,789.24	1,829.30
Goodwill	147.61	168.70
Other Intangible Assets	0.93	0.95
Intangible Assets Under Development	187.25	169.25
Right-of-use assets	18.20	24.27
Financial Assets	-	
Investments	0.01	0.01
Other Financial Assets	378.37	222.93
Other Non-Current Assets	58.41	0.86
Income Tax Assets (Net)	2.43	58.27
Total Non-Current Assets	**2,582.45**	**2,474.54**
Current assets		
Inventories	89.24	83.17
Financial Assets		
Trade Receivables	238.44	217.53
Cash and Cash Equivalents	183.83	195.00
Bank Balances Other than above	17.80	7.74
Other Financial Assets	6.79	6.60
Other Current Assets	11.50	20.44
Total Current Assets	**547.60**	**530.48**
TOTAL ASSETS	**3,130.05**	**3,005.02**
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	1,015.68	1,015.68
Other Equity	1,783.62	1,699.16
Equity attributable to Owners of the Company	**2,799.30**	**2,714.84**
Non Controlling Interest	55.37	49.44
Total Equity	**2,854.67**	**2,764.28**
Liabilities		
Non Current Liabilities		
Financial Liabilities		
Borrowings	-	-
Lease	7.03	13.66
Other financial liabilities	3.85	0.07
Non Current Provision	14.74	14.20
Deferred Tax liabilities (Net)	150.20	146.40
Other Non Current Liabilities	0.13	3.63
Total Non Current Liabilities	**175.95**	**177.96**
Current Liabilities		
Financial Liabilities		
Borrowings	-	-
Lease Liabilities	12.27	10.96
Trade Payables		
Total Outstanding dues of Micro and Small Enterprises	0.72	0.53
Total Outstanding dues of Creditors other than Micro and Small Enterprises	56.41	23.44
Other financial liabilities	10.59	12.97
Other Current Liabilities	13.59	9.09
Current Provision	5.85	5.79
Total Current Liabilities	**99.43**	**62.78**
TOTAL LIABILITIES	**3,130.05**	**3,005.02**

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
(CIN : L85100MH2008PLC179034)
Statement of Consolidated Financial Results for quarter And Half year ended September 30, 2026
All amounts are in Indian Rupees lakhs

Particulars	Quarter ended			Half Year		Year ended
	Sep-26	Jun-26	Sep-25	Sep-26	Sep-25	Mar-26
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
REVENUE						
Revenue from operations (net)	315.07	265.39	297.81	580.46	561.78	1,078.69
Other income	9.20	9.74	9.23	18.94	18.65	39.30
Total Income	**324.27**	**275.13**	**307.04**	**599.40**	**580.43**	**1,117.99**
EXPENSES						
Cost of Materials Consumed	1.03	0.20	0.33	1.23	0.40	4.79
Purchases of stock-in-trade	30.09	29.51	27.92	59.60	53.06	102.16
Changes In Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(1.11)	(4.96)	(0.02)	(6.07)	1.47	(5.17)
Employee benefits expense	24.80	29.06	41.35	53.86	74.81	139.28
Finance costs	0.25	1.19	3.26	1.44	8.60	9.56
Depreciation and amortization expense	35.48	35.45	34.84	70.93	70.51	142.81
Other expenses	158.85	142.62	150.83	301.47	294.55	559.94
Total Expenses	**249.39**	**233.07**	**258.51**	**482.46**	**503.40**	**953.37**
Profit/(Loss) before Exceptional Items & Tax	**74.88**	**42.06**	**48.53**	**116.94**	**77.03**	**164.62**
Exceptional Items	-	-	-	-	-	-
Profit/(Loss) Before Tax	**74.88**	**42.06**	**48.53**	**116.94**	**77.03**	**164.62**
Tax expense:						
Current tax	11.56	11.82	8.56	23.38	16.07	43.19
Deferred tax	(0.53)	4.17	6.82	3.64	6.54	3.32
Profit/(Loss) for the period/year	**63.85**	**26.07**	**33.15**	**89.92**	**54.42**	**118.11**
Items that will not be reclassified to profit or loss :						
Remeasurement of defined employee benefit plans	0.83	(0.20)	0.64	0.63	1.27	1.26
Income tax credit(expense) relating to above items	(0.19)	0.03	(0.01)	(0.16)	(0.17)	(0.25)
Other Comprehensive Income/(Loss) for the year, net of tax	**0.64**	**(0.17)**	**0.63**	**0.47**	**1.10**	**1.01**
TOTAL COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX	**64.49**	**25.90**	**33.78**	**90.39**	**55.52**	**119.12**
Profit/(Loss) for the year attributable to:						
Equity holders of the parent	56.90	27.08	31.20	83.98	56.27	122.82
Non-controlling Interests	6.95	(1.01)	1.92	5.94	(1.85)	(4.71)
Other Comprehensive Income/(Loss) for the year attributable to:						
Equity holders of the parent	0.63	(0.15)	0.53	0.48	0.95	0.94
Non-controlling Interests	0.01	(0.02)	0.10	(0.01)	0.15	0.07
Total Comprehensive Income/(Loss) for the year attributable to:						
Equity holders of the parent	57.53	26.93	32.39	84.46	58.32	123.76
Non-controlling Interests	6.96	(1.03)	1.39	5.93	(2.80)	(4.64)
Paid Up Equity Share Capital (face value 5/- each)	1,015.68	1,015.68	1,015.68	1,015.68	1,015.68	1,015.68
Reserves and surplus during the previous year						1,699.16
Earnings per share (EPS)						
Basic and Diluted Earing Per Share	0.28	0.13	0.17	0.44	0.27	0.61
		Not Annualized				Yearly

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
CIN:L85100MH2008PLC179034
Consolidated Statement of Cash Flows for the Quarter And Half year ended September 30, 2026
All amounts are in Indian Rupees lakhs

Particulars	Period ended September 30, 2026	For year ended March 31,2026
CASH FLOWS FROM OPERATING ACTIVITIES:		
Profit before tax	**116.94**	**164.62**
Adjustments for:		
Depreciation and amortisation expense	70.93	142.81
Finance costs	1.44	9.56
Interest income (classified under investing activities)	(9.75)	(12.90)
Bad debts	-	7.51
Rental income (classified under investing activities)	(7.03)	(13.23)
(Gain) / Loss on sale of property, plant & equipment & Investment property	-	1.08
Provision for Gratuity	1.22	(3.87)
Change in operating assets and liabilities:		
(Increase)/Decrease in trade receivables	(20.90)	(40.14)
(Increase)/Decrease in inventories	(6.07)	(4.17)
Increase/(Decrease) in other financial assets	(155.63)	(40.29)
(Increase) /Decrease in Other assets	7.37	107.24
(Increase)/Decrease in trade payables	33.16	(5.88)
Increase/(Decrease) in Other financial liabilities	1.40	(50.72)
Increase/(Decrease) in other liabilities	1.00	(6.20)
Cash generated from operations	**34.08**	**255.42**
Less: Income taxes (paid)/refund	(23.52)	(83.84)
Net cash flows generated/(used) from operating activities (A)	**10.56**	**171.58**
CASH FLOWS FROM INVESTING ACTIVITIES:		
Payments for property, plant and equipment and intangibles	(21.69)	(51.48)
Proceeds from sale of property, plant and equipment	-	2.25
Proceeds from deletion of intangible	-	-
Intangible asset under development		
Movement in other bank balance	(10.06)	(4.16)
Interest received	9.75	12.90
Dividend received	-	(1.08)
Rental income	7.03	13.23
Net cash flows generated/(used) in investing activities (B)	**(14.97)**	**(28.34)**
CASH FLOWS FROM FINANCING ACTIVITIES:		
Repayment of current borrowings	-	(42.07)
Repayment of non current borrowings	-	(63.20)
Principal element of lease payment	(5.32)	(8.97)
Interest paid	(1.44)	(9.56)
Net cash flows generated/(used) in financing activities (C)	**123.80**	**(123.80)**
Net increase (decrease) in cash and cash equivalents (A+B+C)	1,015.68	19.44
Cash and Cash Equivalents at the beginning of the financial year	195.00	175.56
Cash and Cash Equivalents at end of the year	**1,210.68**	**195.00**
Reconciliation of cash and cash equivalents as per the cash flow statement:		
Cash and cash equivalents as per above comprise of the following:		
Balances with bank in current accounts	92.27	124.41
Cash on hand	91.56	70.59
Balances per statement of cash flows	**183.83**	**195.00**

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

Notes to the Consolidated Financial Results for the period ended September 30, 2026

1. The above Unaudited interim consolidated Financial Results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 12, 2026. The Statutory Auditors have carried out a limited review of the unaudited interim consolidated financial results for the quarter and six months ended September 30, 2026, and have issued an unmodified conclusion thereon.

2. The above consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") 34 – Interim Financial Reporting as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.

3. The accompanying consolidated financial results include the financial results of the subsidiary company, Tejvedaant Healthcare Private Limited.

4. The figures for the quarter ended September 30, 2026, represent the balancing figures between the unaudited figures for the six months ended September 30, 2026, and the published unaudited figures for the quarter ended June 30, 2026, which were subjected to limited review by the Statutory Auditors.

5. The Company's business activity primarily falls within a single reportable business segment namely "Medical and Healthcare Services" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind As 108- "Segment Reporting".

6. Previous year/ period figures have been regrouped to make them comparable with the current year/ period figures, wherever applicable, which are not material.

For and on behalf of Board of Directors of

Tejnaksh Healthcare Limited

Tejnaksh Healthcare Limited MUMBAI

Dr. A. V. Rawandale
Managing Director
DIN: 02005733
Date: November 12, 2026
Place: Mumbai